-
公开(公告)号：US20240182557A1
公开(公告)日：2024-06-06
申请号：US18383310
申请日：2023-10-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
CPC classification number: C07K16/244 , A61K9/0019 , A61K9/08 , A61K39/00 , A61K47/183 , A61K47/22 , A61K47/26 , A61P1/04 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/565
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20240294625A1
公开(公告)日：2024-09-05
申请号：US18401874
申请日：2024-01-02
Applicant: Janssen Biotech, Inc.
Inventor： Omoniyi Adedokun , Jewel Johanns , Katherine Li , Colleen Marano , Christopher O'Brien , Kimberly Shields-Tuttle , Richard Strauss , Hongyan Zhang
IPC: C07K16/24 , A61K9/00 , A61K39/00 , A61K39/395 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/26 , A61P1/04
CPC classification number: C07K16/244 , A61K9/0019 , A61K39/3955 , A61K47/183 , A61K47/20 , A61K47/22 , A61K47/26 , A61P1/04 , A61K2039/505 , C07K2317/565
Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20210171622A1
公开(公告)日：2021-06-10
申请号：US17174201
申请日：2021-02-11
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20210253690A1
公开(公告)日：2021-08-19
申请号：US17175129
申请日：2021-02-12
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
Patent Agency Ranking
公开(公告)号：US20210115129A1
公开(公告)日：2021-04-22
申请号：US17072298
申请日：2020-10-16
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20240002494A1
公开(公告)日：2024-01-04
申请号：US18210885
申请日：2023-06-16
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
CPC classification number: C07K16/244 , A61P1/04 , A61K2039/545
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US10961307B2
公开(公告)日：2021-03-30
申请号：US16580509
申请日：2019-09-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johanns , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
公开(公告)号：US20200095315A1
公开(公告)日：2020-03-26
申请号：US16580509
申请日：2019-09-24
Applicant: Janssen Biotech, Inc.
Inventor： Jewel Johans , Katherine Li , Colleen Marano , Richard Strauss , Hongyan Zhang , Christopher O'Brien , Omoniyi Adedokun , Kimberly Shields-Tuttle
Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.
-
9.发明申请Biomarkers for Anti-TNF Treatment in Ulcerative Colitis and Related Disorders 审中-公开抗TNF治疗溃疡性结肠炎和相关疾病的生物标志物公开(公告)号：US20150184244A1
公开(公告)日：2015-07-02
申请号：US14614826
申请日：2015-02-05
Applicant: Janssen Biotech, Inc.
Inventor： Katherine Li , Frederic Baribaud
IPC: C12Q1/68
CPC classification number: C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158
Abstract: Methods and kits are provided for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis, with at least two genes including BCL6 (Genbank Acc. No. AW264036; SEQ ID NO:118) and tx82a04.x1 (Genbank Acc. No. AI689210; SEQ ID NO:123), optionally further comprising at least one to three of C5AR1 ((Genbank Acc. No.NM001736; SEQ ID NO: 119), FOLR1 ((Genbank Acc. No. U81501; SEQ ID NO: 142) and OSM (Genbank Acc. No. A1079327; SEQ ID NO: 173), optionally further comprising at least one of the listed genes presented in FIG. 7 with a therapeutic response to at least one anti-TNFα agents (e.g., infliximab, golimumab, Enbrel™, Humira™, or other anti-TNF biologic or small molecule drug), in subjects with ulcerative colitis or other gastrointestinal disorder, such as but not limited to Crohn's disease, inflammatory bowel disorder and the like, including mild, moderate, severe, pediatric or adult forms, as well as other forms such as but not limited to steroid, methotrexate or NSAID resistant forms.
Abstract translation: 提供了方法和试剂盒，用于评估受试者中TNF介导相关病症（例如溃疡性结肠炎）的靶向治疗的适用性和/或有效性，该方法和试剂盒评估存在，不存在和/或 与至少两种基因（包括BCL6（Genbank Acc.No.AW264036; SEQ ID NO：118））在炎性胃肠道疾病如溃疡性结肠炎中与抗TNF反应者相关联的上调或下调两个或更多个基因的表达量， 以及tx82a04.x1（Genbank Acc。编号AI689210; SEQ ID NO：123），任选地还包含至少一个到三个C5AR1（（Genbank Acc.No001736; SEQ ID NO：119），FOLR1（（Genbank Acc ，编号U81501; SEQ ID NO：142）和OSM（Genbank Acc.No.A1079327; SEQ ID NO：173），任选地还包含至少一个列于图7中的列出的基因，至少具有至少 一种抗TNFα药物（例如，英夫利昔单抗，戈利木单抗，Enbrel TM，Humira TM或其他抗TNF生物学 gic或小分子药物），在具有溃疡性结肠炎或其它胃肠道疾病的受试者中，例如但不限于克罗恩病，炎症性肠病等，包括轻度，中度，重度，儿科或成人形式，以及其它形式 例如但不限于类固醇，甲氨蝶呤或NSAID抗性形式。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.016 seconds)
